Skip to content

TREAT (Telemedicine for Reach, Education, Access, and Treatment)

TREAT (Telemedicine for Reach, Education, Access, and Treatment)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01339208
Acronym
TREAT
Enrollment
35
Registered
2011-04-20
Start date
2011-06-30
Completion date
2015-03-31
Last updated
2015-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Keywords

Type 2 Diabetes

Brief summary

The purpose of this study is to evaluate the feasibility and clinical efficacy of an innovative care model that combines Telemedicine consultations, educator therapeutic management and diabetes education to empower patients to be in greater control of their own diabetes care for improvements in diabetes outcomes.

Detailed description

This study will assess whether a new care delivery model combining telemedicine videoconference diabetes consultations with diabetes self-management teaching is efficacious in reducing HbA1c in patients with type 2 diabetes in rural areas. The control group will consist of patients with type 2 diabetes receiving usual care, i.e., who have not received a referral to the endocrinologist telemedicine team. Secondary outcomes include patient satisfaction, level of understanding of self-management skills, and hypoglycemia

Interventions

OTHERTelemedicine diabetes intervention

3 month duration telemedicine consultation and diabetes education

Sponsors

United States Department of Defense
CollaboratorFED
University of Pittsburgh
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 18 or older with type 2 diabetes * Referral by a primary care provider. * HbA1c equal or greater than 7.0%.

Exclusion criteria

* Type 1 diabetes * Gestational Diabetes

Design outcomes

Primary

MeasureTime frame
Change in HbA1c % from baseline3 and 6 month

Secondary

MeasureTime frame
Patient satisfaction6 month

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026